| Code | CSB-RA011613MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Hutrukin, targeting interleukin-1 alpha (IL-1α), a potent pro-inflammatory cytokine of the IL-1 family. IL-1α plays a critical role in initiating and amplifying inflammatory responses by binding to the IL-1 receptor type I, triggering downstream signaling cascades that promote the production of additional inflammatory mediators. This cytokine is constitutively expressed in various cell types and functions as both a membrane-bound protein and a secreted factor. IL-1α has been implicated in numerous pathological conditions, including autoinflammatory diseases, rheumatoid arthritis, cardiovascular diseases, and cancer progression, where it contributes to tumor growth, angiogenesis, and metastasis.
Hutrukin (also known as bermekimab) is a therapeutic antibody that has been investigated in clinical trials for conditions such as hidradenitis suppurativa and other IL-1α-mediated inflammatory disorders. This research-grade biosimilar provides investigators with a valuable tool for studying IL-1α biology, exploring inflammatory disease mechanisms, and evaluating potential therapeutic interventions targeting this cytokine pathway in preclinical models.
There are currently no reviews for this product.